Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT for Valeant Pharmaceuticals International

Share:
Related VRX
Mid-Afternoon Market Update: Steelcase Tumbles Following Disappointing Earnings Report; Staples Shares Surge
Mid-Day Market Update: Oracle Surges On Earnings Beat; Kamada Shares Plummet
VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant ... (GuruFocus)

In a report published earlier today, Jefferies & Company, Inc. reiterated its Buy rating for Valeant Pharmaceuticals International, Inc. (NYSE: VRX), but lowered its price target from $75.00 to $63.00.

Jefferies went on to say “After what we viewed as an excellent analyst day yesterday, VRX remains controversial ... yet an excellent investment -- especially after yesterday's weakness. For a company with >20% exposure in Europe, to actually reaffirm the UPPER end of its EPS guidance is a testament to the strength and durability of its business model. We now lower our PT for a more realistic market.”

Valeant Pharmaceuticals International, Inc. closed yesterday at $45.23.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016MizuhoDowngradesNeutralUnderperform

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRX)

View Comments and Join the Discussion!